Overview
The Clinical Proteomics Facility (CPF) was developed in response to UPCI basic and clinical investigators' need for proteomics technology and core expertise, coupled with the great potential of this technology for early detection and assessing response to treatment. Recent publications and results from UPCI researchers demonstrate that proteomics-based research studies, particularly approaches utilizing state-of-the-art mass spectrometry technology for proteomic profiling, offer much promise for molecular diagnosis and classification of human malignancies. These advances are expected to lead to translational applications for improved detection, diagnosis, and prognosis, and also for determining efficacy of treatment of cancer patients.
Accordingly, the CPF was developed to provide proteomics instrumentation, resources, faculty expertise, and trained technical staff to collaboratively assist UPCI basic and clinical researchers in studies focused on the development, validation, and implementation of this technology for cancer early detection biomarkers and screening, clinical diagnostics, and molecular markers for classification, prognosis, and response to therapy.